Company / Operating Cash Flow per Share
Immuneering Corp Operating Cash Flow per Share History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$1.67
FY2023
5-year range
-$2.95 / -$1.67
FY2021-FY2023
Trend
+26.3%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $-2.95 to $-1.67 over the past 2 years.
Based on SEC 10-K filings.
-1.67 in FY2023.
Improved from $-2.95 to $-1.67 over the past 2 years.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, operating cash flow per share increased 26.3% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | -$1.67 | +26.3% |
| FY2022 | -$2.27 | +23.3% |
| FY2021 | -$2.95 | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026